Business Information
The group's principal activities are to discover, develop and market drugs for the treatment of cancer, men's and women's health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases. The group's drug discovery and development programs are based on proprietary gene transcription technology related to intracellular receptors, signal transducers and activators of transcription. The four oncology products marketed in the United States include panretin(R) gel, ontak(R) and targretin(R) capsules and targretin(R) gel. The major customers include eli lilly and company, cardinal health and bergen brunswig drug company.
|
|
Name |
Title
|
Email
|
| John Kozarich | Chmn. | N/A | | John Sharp | VP - Finance, CFO | N/A | | Tod Mertes | VP, Interim CFO | N/A | | Martin Meglasson | VP - Discovery Research | N/A | | Syed Kazmi | VP - Business Development, Strategic Planning | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 140,960 | (31,743) | | 2005 | 176,608 | (36,399) | | 2004 | 163,512 | (45,141)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
